Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Vertebral Artery Rapamycin Target Eluting Stent System Granted CFDA Green-Path


Shanghai, China – On March 22, Vertebral Artery Rapamycin Target Eluting Stent System of MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech"), a wholly owned subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), was granted to enter the special Green-Path by China Food and Drug Administration ("CFDA"), which is rapid-track of review and approval procedure for innovative medical devices. Up to date, a total of 12 products in-house developed by MicroPort® and its subsidiaries have entered Green-Path.
In the cerebrovascular system, vertebral artery is the part most likely to have stenosis other than carotid artery bifurcation. Traditional drugs have limited effect in treating vertebral artery stenosis and are likely to increase the risk of bleeding. On the other hand, open surgery also has its shortcomings in treating the disease such as complex procedure and big trauma. As an emerging technology to treat vertebral artery stenosis, interventional treatment can significantly improve the hemodynamics of narrow vertebral artery, with less complications and good clinical efficacy, which makes it the safest and most effective treatment. However, there is no stent specially designed for the treatment of vertebral artery stenosis, so physicians have to use coronary drug-eluting stents or intracranial artery stents to treat vertebral artery stenosis.
Vertebral Artery Rapamycin Target Eluting Stent System is the world's first drug-eluting stent indicated for the treatment of vertebral artery stenosis. The device design conforms to the anatomical features of vertebral artery, and it has excellent crossability and radial strength. The product adopts target-eluting technology to release the drug from polymer coating to vascular walls with control by drug-eluting technology, which will help to reduce the occurrence rate of vascular restenosis without impacting on the process of vessel endothelialization, ensuring its safety and efficacy at the same time. Vertebral Artery Rapamycin Target Eluting Stent System achieved good clinical trial outcome with significantly lower occurrence rate of vascular restenosis compared to other devices physicians used to treat vertebral artery stenosis.
MicroPort® NeuroTech's Tubridge® Vascular Reconstruction Device ("Tubridge®") was granted CFDA Green-Path in 2015 and gained CFDA approval in March. It is expected that the CFDA Green-Path of Vertebral Artery Rapamycin Target Eluting Stent System will also shorten its approval time to benefit more patients.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® Announces Shareholder Approval for the Acquisition of the Cardiac Rhythm Management Business from LivaNova
[Next]:MicroPort® Attends INDIA LIVE 2018